New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
January 25, 2013
13:25 EDTCTRX, CTRX, CTRX, CVS, CVS, CVS, ESRX, ESRX, ESRXLeerink's healthcare services analyst holds an analyst/industry conference call
Healthcare Technology and Distribution Analyst Larsen discusses the perceived differences between Medco and Express Scripts from the perspective of Managed Care on an Analyst/Industry conference call to be held on January 28 at 2 pm.
News For CTRX;CVS;ESRX From The Last 14 Days
Check below for free stories on CTRX;CVS;ESRX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
April 15, 2014
10:00 EDTCTRXOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
07:20 EDTCTRXCatamaran upgraded to Outperform from Perform at Oppenheimer
Subscribe for More Information
April 14, 2014
15:02 EDTCTRXCatamaran Mat volatility increases, shares near two-year low
Subscribe for More Information
11:09 EDTCTRXOptions with increasing implied volatility: HZNP VJET YOKU CTRX CBS
08:02 EDTCTRXCatamaran recent sell-off overdone, says Jefferies
Jefferies views the recent sell-off in shares of Catamaran as overdone. The firm attributes the move to concerns about the company's ability to meet Q1 consensus and win new contracts. Jefferies expects Catamaran shares to bounce back to the mid-$40s soon after the Q1 report and it keeps a Buy rating on the stock.
April 10, 2014
14:27 EDTCTRXCatamaran sell-off overdone, says UBS
Subscribe for More Information
11:23 EDTCVSRite Aid hits 52-week high after results, sales view top estimates
Shares of retail drugstore Rite Aid (RAD) are rallying after the company's fourth quarter results and fiscal 2015 revenue outlook topped analysts' consensus estimates. WHAT'S NEW: This morning, Rite Aid reported fourth quarter adjusted earnings per share of 10c and revenue of $6.6B, compared to expectations of 4c and $6.54B, respectively. Q4 same store sales increased 2.1%. Rite Aid forecast FY15 EPS of 31c-42c, compared to the consensus of 35c. FY15 revenue was seen at $26B-$26.5B, ahead of the consensus $25.75B. FY15 same-store sales are expected by the company to be up 2.5%-4.5%. WHAT'S NOTABLE: Rite Aid also announced it has acquired RediClinic, which currently operates 30 clinics in the greater Houston, Austin and San Antonio areas. Rite Aid CEO John Standley said, “Our recent acquisitions of Health Dialog and RediClinic, our expanded partnership with McKesson and our continued commitment to investing in our store base have positioned us to transition our strategy from turnaround to growth as we more aggressively pursue opportunities to become a growing retail healthcare company.” PRICE ACTION: In late morning trading, Rite Aid rose 71c, or about 11%, to $7.11 on more than twice its average daily trading volume. Earlier in the session, the stock hit a fresh 52-week high of $7.39. Including today's advance, the stock is up approximately 300% over the past twelve months. OTHERS TO WATCH: Other retail drugstore operators include Walgreen Company (WAG) and CVS Caremark (CVS).
09:23 EDTCTRXCatamaran channel checks cautious, says Cleveland Research
Cleveland Research said Catamaran checks indicate client frustration with customer service and implementation issues. The firm sees downside to 2014 estimates from higher expenses, system upgrades and potential to pay performance guarantees.
April 9, 2014
11:43 EDTESRXGilead defended by analysts after recent pullback
Subscribe for More Information
08:41 EDTESRXAttack on Gilead Sovaldi by Express Scripts 'noise,' says Maxim
After Bloomberg reported that Express Scripts (ESRX) said that it would attempt to build a coalition against the use of Gilead's (GILD) Sovaldi once a rival drug is approved, Maxim views Express Scripts' statement as "noise." The firm says that Sovaldi is not the most expensive HCV drug, and reiterates its view that Sovaldi provides "compelling" value, when including the cost of failure rates in a cost/benefit analysis. Maxim keeps a Buy rating on Gilead.
April 8, 2014
13:24 EDTCVSCVS confirms final SEC settlement, says will not be required to restate earnings
Subscribe for More Information
13:08 EDTCVSCVS Caremark pays $20M to settle SEC accounting charges
The SEC announced that it charged CVS Caremark "with misleading investors about significant financial setbacks and using improper accounting that artificially boosted its financial performance." CVS has agreed to pay $20M to settle the charges, the agency said. Reference Link
April 7, 2014
07:44 EDTCTRXMarketo to hold a summit
Subscribe for More Information
07:24 EDTCVSCVS Caremark price target raised to $84-$89 from $75-$80 at Wells Fargo
Subscribe for More Information
April 4, 2014
10:53 EDTCTRX High option volume stocks: ITW CTRX WMC LQD IMGN
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use